388 related articles for article (PubMed ID: 30627060)
1. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
[TBL] [Abstract][Full Text] [Related]
2. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
3. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
4. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
[TBL] [Abstract][Full Text] [Related]
6. Comparison of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma.
Alexiou GA; Zikou A; Tsiouris S; Goussia A; Kosta P; Papadopoulos A; Voulgaris S; Tsekeris P; Kyritsis AP; Fotopoulos AD; Argyropoulou MI
Magn Reson Imaging; 2014 Sep; 32(7):854-9. PubMed ID: 24848292
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.
Fatterpekar GM; Galheigo D; Narayana A; Johnson G; Knopp E
AJR Am J Roentgenol; 2012 Jan; 198(1):19-26. PubMed ID: 22194475
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression and pseudoresponse in the treatment of gliomas.
Brandsma D; van den Bent MJ
Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
12. Pseudoprogression in high-grade glioma.
Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
Delgado-López PD; Riñones-Mena E; Corrales-García EM
Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis.
Masch WR; Wang PI; Chenevert TL; Junck L; Tsien C; Heth JA; Sundgren PC
Acad Radiol; 2016 May; 23(5):569-76. PubMed ID: 26916251
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Khan UA; Rennert RC; White NS; Bartsch H; Farid N; Dale AM; Chen CC
J Clin Neurosci; 2018 Dec; 58():136-141. PubMed ID: 30253908
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
17. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
Front Immunol; 2021; 12():790674. PubMed ID: 34899760
[TBL] [Abstract][Full Text] [Related]
18. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment Evaluation of Brain Gliomas.
Dalesandro MF; Andre JB
Neuroimaging Clin N Am; 2016 Nov; 26(4):581-599. PubMed ID: 27712795
[TBL] [Abstract][Full Text] [Related]
20. The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.
Santo G; Laudicella R; Linguanti F; Nappi AG; Abenavoli E; Vergura V; Rubini G; Sciagrà R; Arnone G; Schillaci O; Minutoli F; Baldari S; Quartuccio N; Bisdas S
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
